January 31, 2025 expert reaction to NICE final draft guidance on exagamglogene autotemcel (exa-cel) for severe sickle cell disease . Scientists comment on final draft guidance fro ...
Hosted on MSN2mon
Makers of Sickle Cell Disease Gene Therapy to Participate in Payment Model, CMS SaysVertex makes exagamglogene autotemcel (Casgevy) while bluebird bio manufactures lovotibeglogene autotemcel (Lyfgenia). In addition to improving outcomes, the Center for Medicare and Medicaid ...
CASGEVY ® (exagamglogene autotemcel). The reimbursement agreement comes as the National Institute for Health and Care Excellence (NICE) issues positive guidance recommending CASGEVY’s use in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback